This website uses cookies to enhance your browsing experience, improve site performance, and gather analytics. By selecting 'Accept,' you consent to these cookies as described in our Privacy Policy.

Aveir DR i2i Study

Sponsored by Abbott Medical Devices

About this trial

Last updated 8 months ago

Study ID

ABT-CIP-10416

Status

Active not recruiting

Type

Interventional

Phase

N/A

Placebo

No

Accepting

18+ Years
All Sexes

Trial Timing

Ended 5 months ago

What is this trial about?

Prospective, non-randomized, multi-center, international study designed to evaluate the safety and effectiveness of the Aveir™ Dual-Chamber (DR) Leadless Pacemaker system.

What are the participation requirements?

Inclusion Criteria

1. Subject must have at least one of the clinical indications before device implant in adherence with ACC/AHA/HRS/ESC dual chamber pacing guidelines

2. Subject is ≥ 18 years of age or age of legal consent, whichever age is greater

3. Subject has a life expectancy of at least one year

4. Subject is willing to comply with clinical investigation procedures and agrees to return to clinic for all required follow-up visits, tests, and exams

5. Subject has been informed of the nature of the clinical investigation, agrees to its provisions and has provided a signed written informed consent, approved by the IRB/EC

Exclusion Criteria

1. Subject is currently participating in another clinical investigation that may confound the results of this study as determined by the Sponsor

2. Subject is pregnant or nursing and those who plan pregnancy during the clinical investigation follow-up period

3. Subject has presence of anatomic or comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, could confound the assessment of the investigational device and/or implant procedure, limit the subject's ability to participate in the clinical investigation or to comply with follow-up requirements of the clinical investigation results

4. Subject has a known allergy or hypersensitivity to < 1 mg of dexamethasone sodium phosphate or any blood or tissue contacting material listed in the IFU

5. Subject has an implanted vena cava filter or mechanical tricuspid valve prosthesis

6. Subject has pre-existing, permanent endocardial pacing or defibrillation leads (does not include lead fragments)

7. Subject has current implantation of either conventional or subcutaneous implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy (CRT) device

8. Subject has an implanted leadless cardiac pacemaker (except for an Aveir ventricular leadless pacemaker)

9. Subject is implanted with an electrically-active implantable medical device with stimulation capabilities (such as neurological or cardiac stimulators)

10. Subject is unable to read or write